查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088684

甲狀腺癌診斷市場：按技術、檢體類型、生物標記類型、應用和最終用戶分類－2026-2032年全球市場預測

Thyroid Cancer Diagnostics Market by Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，甲狀腺癌診斷市場將成長至 57.1 億美元，複合年成長率為 7.35%。

主要市場統計數據
基準年 2025 34.8億美元
預計年份：2026年 37.2億美元
預測年份 2032 57.1億美元
複合年成長率 (%) 7.35%

甲狀腺癌的診斷正從單一檢測轉向對甲狀腺結節進行綜合評估，結合高解析度超音波、細針穿刺細胞學檢查、分子診斷、血清生物標記和基於風險的後續觀察。這項轉變具有重要的臨床意義，因為世界衛生組織/國際癌症研究機構的《2022年全球甲狀腺癌預測》（GLOBOCAN 2022）估計，全球新增甲狀腺癌病例超過82萬例，使其成為最常見的內分泌惡性腫瘤之一。

需求成長的促進因素包括甲狀腺結節檢出率的提高、影像診斷的普及、基於貝塞斯達系統的細胞病理學診斷的廣泛應用，以及旨在區分進展緩慢的乳頭狀甲狀腺癌與更具侵襲性的疾病的指南制​​定工作。對於診斷設備製造商、實驗室、醫院和影像網路而言，最大的成長機會在於檢測能夠增強臨床信心、減少不必要的切除術切除術，並支持針對BRAF、RAS、RET、NTRK、TERT和其他具有治療意義的突變進行精準腫瘤學決策。

一項將重塑甲狀腺癌診斷的變革性改變。

甲狀腺癌的診斷格局正因三個循​​證醫學證據支持的變革而發生轉變：更嚴格的基於超音波的風險分層、對診斷不明確的結節更多地採用分子檢測，以及病理科和腫瘤科之間更緊密的合作。諸如ACR TI-RADS和ATA超音波模式等系統正在規範影像診斷的解讀，而Bethesda細胞學分類則繼續作為細針穿刺切片檢查的指南。

人工智慧對診斷準確性的累積影響

人工智慧（AI）並非旨在完全取代臨床醫生，而是對整個甲狀腺癌診斷流程產生累積影響。在超音波影像成像領域，人工智慧模型正被用於對可疑甲狀腺結節進行分類、評估惡性風險、輔助病灶分割以及減少放射科醫生之間的差異。在細胞病理學領域，機器學習可以輔助進行切片閱片、細胞模式識別以及篩選需要專家評估的病例。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

由於亞太地區甲狀腺癌患者群體龐大，超音波檢查普及率不斷提高，以及中國、日本、韓國、澳洲和印度等國擁有完善的診斷基礎設施，該地區對甲狀腺癌診斷的需求正迅速成長。北美地區仍然是甲狀腺癌診斷領域的領先地區，這得益於美國和加拿大先進的內分泌腫瘤網路、分子檢測的廣泛應用以及完善的臨床指南。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約市場的關鍵群體特定見解。

在東協市場，隨著都市區醫院不斷擴大服務範圍，內分泌影像和細胞學服務的重要性日益凸顯。新加坡、泰國、馬來西亞、印尼、越南和菲律賓等國在甲狀腺癌分子診斷的準備程度有差異。海灣合作理事會（GCC）地區的特點是醫療保健領域的大量投資、先進影像技術的快速普及以及能夠支持甲狀腺癌基因組檢測的集中式癌症治療模式。

主要國家甲狀腺癌診斷引入趨勢

美國在甲狀腺癌分子診斷、人工智慧影像評估和內分泌腫瘤專科臨床路徑方面處於主導。而加拿大則強調透過其省級醫療保健系統推廣實證醫學。墨西哥和巴西的超音波和細胞學檢查服務正在不斷普及，尤其是巴西，憑藉其不斷壯大的參考實驗室和醫院分子檢測能力，為拉丁美洲提供了巨大的發展機會。

為行業領導者提供的實用建議

產業領導者應檢驗經臨床驗證的甲狀腺結節診斷方法，以減少不必要的手術，改善細胞學結果不明確的個案管理，並符合基於ATA、NCCN、ACR TI-RADS和Bethesda標準的流程。產品必須透過真實世界數據、衛生經濟學結果以及清晰易懂、便於臨床醫生使用的報告來證明其效用。

基於證據的市場分析調查方法

本執行摘要基於系統性的調查方法，該方法結合了二手資料研究、監管審查、臨床指南分析和市場三角驗證。主要證據來源包括世衛組織/國際癌症研究機構GLOBOCAN癌症統計數據、美國甲狀腺協會（ATA）和美國國家綜合癌症網路（NCCN）甲狀腺癌指南、美國放射學會（ACR）甲狀腺影像報告和數據系統（TI-RADS）建議、貝塞斯達系統細胞病理學標準、同行評審的人工智慧和分子診斷文獻，以及美國食品藥品監督機構（FDA）和歐盟藥物機構的資訊機構（FDA）的人工智慧和分子診斷文獻，以及美國食品藥物管理局（FDA）和歐盟藥物機構的資訊委員會發布。

結論：準確性和工作流程的整合將決定未來。

甲狀腺癌的診斷正朝著更精準、互聯和循證的方向發展。市場不再僅限於檢測惡性腫瘤，而是越來越注重識別哪些結節需要干預，哪些患者可以安全地後續觀察，以及哪些晚期癌症需要標靶治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 甲狀腺癌診斷市場：依技術分類

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
  • 免疫組織化學
  • 次世代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因測序
  • 即時PCR
    • 數位PCR
    • qPCR

第8章：甲狀腺癌診斷市場：依樣本類型分類

  • 血液檢體
  • 細針穿刺切片檢查
  • 組織切片檢查

第9章：甲狀腺癌診斷市場：依生物標記類型分類

  • 表觀遺傳標記
    • DNA甲基化
    • miRNA
  • 遺傳標記
    • BRAF
    • RAS
    • TERT
  • 蛋白質標記物
    • 抑鈣素
    • 甲狀腺球蛋白

第10章：甲狀腺癌診斷市場：依應用分類

  • 診斷
  • 預後
  • 復發監測
  • 治療監測

第11章 甲狀腺癌診斷市場：依最終用戶分類

  • 學術研究機構
    • 癌症研究中心
    • 大學研究所
  • 門診部
    • 診斷影像中心
    • 專科診所
  • 研究所
    • 鏈實驗室
    • 獨立檢測實驗室
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 甲狀腺癌診斷市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 甲狀腺癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 甲狀腺癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Guardant Health, Inc.
  • Hitachi High-Tech Corporation
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Mindray Bio-Medical Electronics Co., Ltd.
  • Myriad Genetics, Inc.
  • QIAGEN NV
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A339DAEFAACE

The Thyroid Cancer Diagnostics Market is projected to grow by USD 5.71 billion at a CAGR of 7.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.48 billion
Estimated Year [2026] USD 3.72 billion
Forecast Year [2032] USD 5.71 billion
CAGR (%) 7.35%

Thyroid cancer diagnostics are moving from single-test detection toward integrated thyroid nodule evaluation that combines high-resolution ultrasound, fine-needle aspiration cytology, molecular diagnostics, serum biomarkers, and risk-adapted follow-up. This shift is clinically important because WHO/IARC GLOBOCAN 2022 estimated more than 820,000 new thyroid cancer cases worldwide, making thyroid cancer one of the most frequently diagnosed endocrine malignancies.

Demand is being shaped by rising detection of thyroid nodules, broader access to imaging, expanding use of Bethesda System cytopathology, and guideline-driven efforts to distinguish indolent papillary thyroid cancer from aggressive disease. For diagnostic companies, laboratories, hospitals, and imaging networks, the growth opportunity is strongest where tests improve clinical confidence, reduce unnecessary thyroidectomy, and support precision oncology decisions for BRAF, RAS, RET, NTRK, TERT, and other actionable alterations.

Transformative Shifts Reshaping Thyroid Cancer Diagnostics

The thyroid cancer diagnostics landscape is being transformed by three evidence-based shifts: more disciplined ultrasound risk stratification, wider use of molecular testing for indeterminate nodules, and tighter integration between pathology and oncology. Systems such as ACR TI-RADS and ATA ultrasound patterns have made imaging interpretation more standardized, while Bethesda cytology categories continue to guide fine-needle aspiration management.

Molecular diagnostics are changing the value proposition. Rule-out and rule-in assays help clinicians manage Bethesda III and IV nodules, and next-generation sequencing panels can identify mutations and fusions relevant to targeted therapy in advanced thyroid cancer. At the same time, laboratories are adapting to stricter quality, reimbursement, and regulatory expectations, including the EU In Vitro Diagnostic Regulation and heightened scrutiny of laboratory-developed tests in the United States.

Cumulative Impact of Artificial Intelligence on Diagnostic Accuracy

Artificial intelligence is having a cumulative impact across the thyroid cancer diagnostics workflow rather than replacing clinicians outright. In ultrasound imaging, AI models are being developed to classify suspicious thyroid nodules, estimate malignancy risk, support lesion segmentation, and reduce inter-reader variability. In cytopathology, machine learning can assist slide review, cell pattern recognition, and triage of cases that require expert assessment.

The commercial value of AI depends on external validation, explainability, workflow integration, and performance across diverse populations. Peer-reviewed literature shows promising accuracy for thyroid nodule classification, but real-world adoption requires prospective validation, bias monitoring, cybersecurity safeguards, and clear clinical responsibility. The strongest near-term use cases are decision support, quality control, and prioritization of high-risk cases in imaging centers and pathology laboratories.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific represents a high-volume growth arena for thyroid cancer diagnostics due to large patient populations, expanding ultrasound access, and strong diagnostic infrastructure in China, Japan, South Korea, Australia, and increasingly India. North America remains a premium adoption region, supported by advanced endocrine oncology networks, broad molecular testing use, and established clinical guidelines in the United States and Canada.

Europe is defined by guideline consistency, public health systems, and the transition to EU IVDR-compliant diagnostic evidence, creating demand for clinically validated assays and traceable laboratory workflows. Latin America, led by Brazil and Mexico, is expanding access to ultrasound-guided fine-needle aspiration and reference laboratory testing, although reimbursement variability affects molecular test uptake.

The Middle East is investing in tertiary cancer centers, genomic medicine, and private hospital capacity, especially across GCC countries. Africa remains underpenetrated but strategically important, with opportunities tied to ultrasound availability, pathology workforce development, referral networks, and affordable thyroid cancer diagnostic tests that can be deployed across public health systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are gaining relevance as urban hospitals expand endocrine imaging and cytology services, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different levels of readiness for molecular thyroid cancer diagnostics. The GCC is characterized by high healthcare investment, fast adoption of advanced imaging, and centralized cancer care models that can support genomic testing for thyroid cancer.

The European Union is a major regulatory and evidence-generation hub because EU IVDR is increasing requirements for clinical performance, post-market surveillance, and laboratory quality documentation. BRICS countries collectively represent scale, with China, India, Brazil, Russia, and South Africa offering large patient pools but uneven access to advanced diagnostics.

G7 countries lead in premium diagnostics adoption, clinical guideline development, reimbursement sophistication, and integration of molecular testing into oncology pathways. NATO markets overlap with many high-income healthcare systems and are relevant for supply-chain resilience, cybersecurity standards, laboratory interoperability, and cross-border diagnostic technology procurement.

Key Country Insights for Thyroid Cancer Diagnostics Adoption

The United States leads in molecular thyroid cancer diagnostics, AI-enabled imaging evaluation, and specialized endocrine oncology pathways, while Canada emphasizes evidence-based adoption through provincial health systems. Mexico and Brazil are expanding ultrasound and cytology access, with Brazil offering a major Latin American opportunity for reference laboratory growth and hospital-based molecular testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established pathology networks, national cancer strategies, and growing use of risk-stratified thyroid nodule management. Russia has strong tertiary care capacity in major cities but faces access variability across regions.

China is scaling thyroid ultrasound, hospital-based pathology, and domestic molecular testing at significant volume. India presents long-term growth driven by population scale, urban specialty care, and private diagnostics expansion, while Japan and South Korea are advanced markets with high imaging penetration and sophisticated cancer centers. Australia combines guideline-led practice with strong pathology standards and digital health adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated thyroid nodule diagnostics that reduce unnecessary surgery, improve indeterminate cytology management, and align with ATA, NCCN, ACR TI-RADS, and Bethesda-based workflows. Products should demonstrate utility through real-world evidence, health-economic outcomes, and clear reporting that clinicians can act on.

Organizations should invest in interoperable platforms connecting ultrasound, cytology, molecular results, and longitudinal surveillance data. AI developers must focus on diverse training datasets, transparent performance metrics, prospective validation, and integration into radiology and pathology workflows. Commercial teams should tailor strategies by region, pairing premium genomic testing in mature markets with affordable ultrasound-guided cytology and centralized reference testing in emerging markets.

Research Methodology for Evidence-Based Market Analysis

This executive summary is grounded in a structured research methodology combining secondary research, regulatory review, clinical guideline analysis, and market triangulation. Core evidence sources include WHO/IARC GLOBOCAN cancer statistics, ATA and NCCN thyroid cancer guidance, ACR TI-RADS recommendations, Bethesda System cytopathology standards, peer-reviewed AI and molecular diagnostics literature, and public regulatory information from agencies such as the FDA and European Commission.

Insights were evaluated across test modality, clinical utility, reimbursement environment, regional infrastructure, and adoption barriers. Country and group-level assessments considered healthcare capacity, diagnostic access, oncology referral systems, laboratory maturity, and policy trends. The approach emphasizes verified, data-backed interpretation and avoids unsupported sizing or forecasting claims.

Conclusion: Precision and Workflow Integration Define the Future

Thyroid cancer diagnostics are entering a more precise, connected, and evidence-driven phase. The market is no longer defined only by detecting malignancy; it is increasingly focused on identifying which nodules require intervention, which patients can be monitored safely, and which advanced cancers need targeted therapy selection.

Growth will favor organizations that combine clinical credibility, workflow efficiency, molecular depth, AI-enabled decision support, and regional adaptability. As incidence, imaging utilization, and precision oncology expand, thyroid cancer diagnostics will remain a high-value segment for laboratories, imaging providers, device manufacturers, software developers, and integrated cancer care networks.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Thyroid Cancer Diagnostics Market, by Technology

  • 7.1. Immunoassay
    • 7.1.1. Chemiluminescence Immunoassay
    • 7.1.2. ELISA
  • 7.2. Immunohistochemistry
  • 7.3. Next Generation Sequencing
    • 7.3.1. Targeted Sequencing
    • 7.3.2. Whole Exome Sequencing
    • 7.3.3. Whole Genome Sequencing
  • 7.4. Real Time PCR
    • 7.4.1. Digital PCR
    • 7.4.2. qPCR

8. Thyroid Cancer Diagnostics Market, by Sample Type

  • 8.1. Blood Sample
  • 8.2. Fine Needle Aspiration
  • 8.3. Tissue Biopsy

9. Thyroid Cancer Diagnostics Market, by Biomarker Type

  • 9.1. Epigenetic Markers
    • 9.1.1. DNA Methylation
    • 9.1.2. miRNA
  • 9.2. Genetic Markers
    • 9.2.1. BRAF
    • 9.2.2. RAS
    • 9.2.3. TERT
  • 9.3. Protein Markers
    • 9.3.1. Calcitonin
    • 9.3.2. Thyroglobulin

10. Thyroid Cancer Diagnostics Market, by Application

  • 10.1. Diagnosis
  • 10.2. Prognosis
  • 10.3. Recurrence Monitoring
  • 10.4. Therapy Monitoring

11. Thyroid Cancer Diagnostics Market, by End User

  • 11.1. Academic Research Institutes
    • 11.1.1. Cancer Research Centers
    • 11.1.2. University Laboratories
  • 11.2. Ambulatory Care Centers
    • 11.2.1. Imaging Centers
    • 11.2.2. Specialized Clinics
  • 11.3. Laboratories
    • 11.3.1. Chain Laboratories
    • 11.3.2. Independent Laboratories
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Thyroid Cancer Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Thyroid Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Thyroid Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Becton, Dickinson and Company
  • 16.3. bioMerieux S.A.
  • 16.4. Bruker Corporation
  • 16.5. Canon Medical Systems Corporation
  • 16.6. Danaher Corporation
  • 16.7. DiaSorin S.p.A.
  • 16.8. Exact Sciences Corporation
  • 16.9. F. Hoffmann-La Roche Ltd
  • 16.10. Foundation Medicine, Inc.
  • 16.11. Fujifilm Holdings Corporation
  • 16.12. GE HealthCare Technologies Inc.
  • 16.13. Guardant Health, Inc.
  • 16.14. Hitachi High-Tech Corporation
  • 16.15. Hologic, Inc.
  • 16.16. Illumina, Inc.
  • 16.17. Koninklijke Philips N.V.
  • 16.18. Mindray Bio-Medical Electronics Co., Ltd.
  • 16.19. Myriad Genetics, Inc.
  • 16.20. QIAGEN N.V.
  • 16.21. Seegene Inc.
  • 16.22. Siemens Healthineers AG
  • 16.23. Sysmex Corporation
  • 16.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL THYROID CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL QPCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL QPCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL QPCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD SAMPLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD SAMPLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD SAMPLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FINE NEEDLE ASPIRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EPIGENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA METHYLATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA METHYLATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA METHYLATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIRNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MIRNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIRNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENETIC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENETIC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENETIC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TERT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TERT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TERT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROTEIN MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROTEIN MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROTEIN MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CALCITONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CALCITONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CALCITONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THYROGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THYROGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RECURRENCE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THERAPY MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THERAPY MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL THERAPY MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER RESEARCH CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL UNIVERSITY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SPECIALIZED CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CHAIN LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INDEPENDENT LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 244. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 246. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 250. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 251. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 255. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 256. GCC THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 292. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 293. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 294. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 297. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 298. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 299. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 302. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 304. G7 THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 305. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 309. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 310. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 313. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 314. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 315. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 316. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 318. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 319. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 320. NATO THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 321. GLOBAL THYROID CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MARKERS, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES THYROID CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 341. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 342. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2032 (USD MILLION)
  • TABLE 343. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. CANADA THYROID CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. CANADA THYROID CANCER DIAGNO